Clinical Trial Update: SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 neoadjuvant study of SHR-A1811 alone or with adebrelimab for HR-positive/HER2-low breast cancer; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• SHR-A1811

Snippet

Sponsor: Shengjing Hospital | Conditions: HR Positive/HER2 Low Breast Cancer | Phase 2 | Status: RECRUITING